pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,199 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1169Endpoints883BioPharma Dive340BioSpace303Fierce Biotech283onclive165raps104globenewswire health73
therapy area
allOncology7505Rare Disease1856Cardiology1708Immunology1472Hematology1313Vaccines1192Pulmonology
  • 23andMe partners with HealthEx to let users import medical records for a 360-degree health view
    23andMe announced a partnership with HealthEx that will let its customers import their medical records, creating a more complete view of personal health. The new feature will combine genetic data…
    STAT · 3mo agoDealPositive↗ source
  • Supreme Court refuses to hear pharma challenges to Medicare price negotiation program
    The U.S. Supreme Court declined to review lawsuits filed by several brand‑name drug makers against the Medicare drug price negotiation program, dealing a significant setback to the industry. The c…
    STAT · 3mo agoRegulatoryNegative↗ source
← prev
page 74 of 88
next →
fda medwatch65
fda recalls62
fda press38
1127
Psychiatry & CNS864
Ophthalmology494
Pain478
Endocrinology & Metabolism468
Infectious Disease444
  • Mentari Therapeutics to go public via reverse merger with InMed, raising $290 million for migraine antibody programs
    Mentari Therapeutics, a spinout of Paragon, announced a reverse merger with InMed Pharmaceuticals that will take the company public under the Mentari name. The deal has received board approval fro…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Virginia Governor Vetoes Bill to Create Drug-Cost Advisory Panel Using Medicare Benchmarks
    Virginia's governor, Abigail Spanberger, vetoed a bill that would have created a new advisory panel aimed at lowering prescription-drug costs. The legislation had been closely watched as a potentia…
    STAT · 3mo agoRegulatoryNegative↗ source
  • AI tool guides Mayo clinicians to rapid treatment for newborn with ultra-rare disease
    An AI system called the Biomedical Data Translator was used by doctors at the Mayo Clinic to search for a therapy for a newborn with an ultra-rare disease. The infant, Jorie Kraus, was born with s…
    STAT · 3mo agoPositive↗ source
  • Former FDA commissioner sees hope for stability under new acting leader Kyle Diamantas
    At a recent STAT Breakthrough Summit West, former FDA commissioner David Kessler addressed concerns about the agency’s recent turmoil and staff departures. Kessler said the appointment of acting c…
    STAT · 3mo agoRegulatoryPositive↗ source
  • BioMarin's BMN-401 fails key endpoint in ENPP1 deficiency Phase 3 trial
    An experimental therapy, BMN 401, was tested in a Phase 3 study for ENPP1 deficiency, a rare disease. The drug missed one of its two co-primary endpoints, a result that regulators consider critical…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Relay Therapeutics reports promising Phase 2 results for zovegalisib; Eli Lilly leads R&D performance ranking
    Relay Therapeutics announced positive Phase 2 data for its experimental drug zovegalisib, which targets rare diseases that cause abnormal blood vessel development. The company said the results were…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomalies
    Relay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vesse…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Eli Lilly Leads Both Innovation and Invention Rankings in Pharma R&D Performance
    STAT+ reports that Eli Lilly captured the top positions in a prominent pharma R&D performance ranking, leading both the innovation and invention categories. The rankings, compiled by UK-based IDEA…
    STAT · 3mo agoPositive↗ source
  • Over 1 in 8 U.S. Pregnant Women Report Alcohol Use, Raising Fetal Health Concerns
    More than one in eight pregnant adults in the United States reported drinking in the past month, according to STAT's analysis of 2024 government data, making alcohol use more common than gestationa…
    STAT · 3mo agoNegative↗ source
  • UK adopts tobacco-free generation law, mirroring Massachusetts policy
    The United Kingdom has passed a tobacco‑free generation law that bars retailers from selling cigarettes, vapes or nicotine pouches to anyone born on or after Jan. 1, 2009. Existing customers may co…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Heart transplant patient warns of 'ghost approval' gap that leaves life-saving drugs out of reach
    A heart transplant recipient and patient advocate describes how the medication everolimus (Zortress) is essential to prevent organ rejection, not an optional treatment. The author coins the term "…
    STAT · 3mo agoNegative↗ source
  • Trump-era foreign aid cuts likely hampered Ebola detection and response in Congo
    The United States reduced funding for programs that help prevent and control infectious diseases in the Democratic Republic of Congo during the final months before a fast-moving Ebola outbreak, acc…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Out-of-network spine surgery bills soar to $34,000 under No Surprises Act arbitration
    A new analysis shows that the median price for a lumbar laminectomy, a common spine surgery, is about $1,400 when performed by in-network providers. When the same procedure is done by out-of-netwo…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Study finds many Canadian medical societies lack robust conflict-of-interest policies
    A new analysis of 68 Canadian medical societies shows that just under half have comprehensive conflict-of-interest policies. The researchers identified that 35 societies, or about 52%, do not addre…
    STAT · 3mo agoNegative↗ source
  • TrumpRx expands generic drug lineup through partnership with Mark Cuban, Amazon Pharmacy and GoodRx
    TrumpRx said it is adding a range of generic medicines to its portfolio after striking a deal that includes Mark Cuban, Amazon Pharmacy and GoodRx. The agreement is expected to broaden the company…
    STAT · 3mo agoDealNeutral↗ source
  • Dexcom CEO discusses future applications of continuous glucose monitors and provides updates on WiSeR and Epic market share
    Dexcom's chief executive spoke about potential new uses for the company's continuous glucose monitoring technology, suggesting that the device could play a broader role in health management beyond…
    STAT · 3mo agoNeutral↗ source
  • Former Stanford President Marc Tessier-Lavigne Addresses Allegations in New Book
    Former Stanford President Marc Tessier-Lavigne, now chief executive of AI drug‑discovery startup Xaira, spoke publicly for the first time at the STAT Breakthrough Summit West in San Francisco. Dur…
    STAT · 3mo agoNeutral↗ source
  • U.S. imposes 30‑day travel ban on travelers from DRC, Uganda, South Sudan amid Ebola outbreak
    The CDC announced a new order that bars anyone who has been in the Democratic Republic of the Congo, Uganda, or South Sudan within the past 21 days from entering the United States. The restriction…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • FDA approves AstraZeneca’s novel hypertension pill Baxfendy
    The U.S. Food and Drug Administration has cleared AstraZeneca’s new hypertension medication, Baxfendy, marking the first approval of a drug that works by inhibiting a blood‑pressure‑raising enzyme.…
    BioPharma Dive · 3mo agoApprovalPositive↗ source
  • Merck's China-sourced ADC shows survival benefit in Phase 3 endometrial cancer trial
    Merck & Co., in partnership with Chinese biotech Kelun-Biotech, reported that its experimental antibody-drug conjugate sacituzumab tirumotecan (Sac-TMT) met its primary endpoint in a global Phase 3…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • FDA leadership overhaul follows firing of acting CDER director; 20 deaths linked to Amgen’s Tavneos in Japan
    The FDA announced another leadership change, removing acting directors of its two main drug review centers. Tracy Beth Høeg, acting head of the Center for Drug Evaluation and Research (CDER), poste…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • China's rapid drug development fuels split among U.S. biotech firms
    Damian Garde spoke with more than a dozen investors, entrepreneurs and industry leaders about how China's growing role is reshaping U.S. biotech strategy. American companies have poured roughly $6…
    STAT · 3mo agoNeutral↗ source
  • AstraZeneca receives FDA approval for new hypertension medication
    AstraZeneca announced that the U.S. Food and Drug Administration has approved its hypertension drug, marking a regulatory milestone for the company. The approval adds to AstraZeneca's cardiovascul…
    STAT · 3mo agoApprovalPositive↗ source